- Phase 3 trial of firmonertinib monotherapy in previously untreated non-squamous non-small cell lung cancer.
- Primary endpoint: progression-free survival vs chemotherapy.
- No meaningful improvement observed.
- Safety profile consistent with prior studies.
- Stock fell 59% to $11.77 in premarket trading.
- CEO Bing Yao stated the company is evaluating the full dataset.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card